This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Deactylase inhibition in myeloproliferative neoplasms
Investigational New Drugs Open Access 03 December 2010
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tefferi A, Vardiman JW . Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22.
Cervantes F, Mesa R, Barosi G . New and old treatment modalities in primary myelofibrosis. Cancer J 2007; 13: 377–383.
Levine RL, Pardanani A, Tefferi A, Gilliland DG . Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673–683.
Pardanani A . JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials. Leukemia 2008; 22: 23–30.
Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA . Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007; 21: 1827–1828.
Wagner-Ballon O, Pisani DF, Gastinne T, Tulliez M, Chaligne R, Lacout C et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice. Blood 2007; 110: 345–353.
Shetty V, Verspoor F, Nguyen H, Gallegos A, Mundle S, Chaudry N . Effect of proteosome inhibition by bortezomib on tumor necrosis factor-alpha (TNF-alpha) and aopotosis in patients with Myelodysplastic Syndromes. Blood 2003; 106 (Suppl 1): a1534.
Barosi G, Gattoni E, Barbui T, Vannucchi AM, Rambaldi A, Silverman L et al. A phase I study of the proteasome inhibitor bortezomib in patients with myelofibrosis. Blood 2007; 110: a3540.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mesa, R., Verstovsek, S., Rivera, C. et al. Bortezomib therapy in myelofibrosis: a phase II clinical trial. Leukemia 22, 1636–1638 (2008). https://doi.org/10.1038/leu.2008.32
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2008.32
This article is cited by
-
Therapy of myelofibrosis (excluding JAK2 inhibitors)
International Journal of Hematology (2010)
-
Deactylase inhibition in myeloproliferative neoplasms
Investigational New Drugs (2010)
-
5-Azacitidine has limited therapeutic activity in myelofibrosis
Leukemia (2009)